Robotic versus Laparoscopic versus Open Gastrectomy: A Meta-Analysis. by 源��쑀誘� et al.
Original Article
Robotic versus Laparoscopic versus Open Gastrectomy:  
A Meta-Analysis
Alessandra Marano1,4,*, Yoon Young Choi1,*, Woo Jin Hyung1,2, Yoo Min Kim1, Jieun Kim3, and Sung Hoon Noh1
1Department of Surgery, Yonsei University College of Medicine, 2Robot and MIS Center, Severance Hospital, 
Yonsei University Health System, 3Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Korea, 
4Department of General and Oncologic Surgery, SS Antonio and Biagio Hospital, Alessandria, University of Turin, Turin, Italy
Purpose: To define the role of robotic gastrectomy for the treatment of gastric cancer, the present systematic review with meta-analysis 
was performed.
Materials and Methods: A comprehensive search up to July 2012 was conducted on PubMed, EMBASE, and the Cochrane Library. All 
eligible studies comparing robotic gastrectomy versus laparoscopic gastrectomy or open gastrectomy were included.
Results: Included in our meta-analysis were seven studies of 1,967 patients that compared robotic (n=404) with open (n=718) or 
laparoscopic (n=845) gastrectomy. In the complete analysis, a shorter hospital stay was noted with robotic gastrectomy than with open 
gastrectomy (weighted mean difference: -2.92, 95% confidence interval: -4.94 to -0.89, P=0.005). Additionally, there was a signifi-
cant reduction in intraoperative blood loss with robotic gastrectomy compared with laparoscopic gastrectomy (weighted mean difference: 
-35.53, 95% confidence interval: -66.98 to -4.09, P=0.03). These advantages were at the price of a significantly prolonged operative 
time for both robotic gastrectomy versus laparoscopic gastrectomy (weighted mean difference: 63.70, 95% confidence interval: 44.22 
to 83.17, P<0.00001) and robotic gastrectomy versus open gastrectomy (weighted mean difference: 95.83, 95% confidence interval: 
54.48 to 137.18, P<0.00001). Analysis of the number of lymph nodes retrieved and overall complication rates revealed that these 
outcomes did not differ significantly between the groups.
Conclusions: Robotic gastrectomy for gastric cancer reduces intraoperative blood loss and the postoperative hospital length of stay com-
pared with laparoscopic gastrectomy and open gastrectomy at a cost of a longer operating time. Robotic gastrectomy also provides an 
oncologically adequate lymphadenectomy. Additional high-quality prospective studies are recommended to better evaluate both short 
and long-term outcomes.
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Introduction
Minimally invasive surgery (MIS) has enjoyed wide accep-
tance since the first laparoscopic gastrectomy (LG) for cancer was 
reported in 1994.1,2 Numerous approaches to this procedure have 
been developed, and many patients have benefited from their ef-
fectiveness. This is particularly salient as recently demonstrated by 
phase III clinical trials for early gastric cancer.3-5 However, lapa-
roscopic surgery has certain limitations, such as two-dimensional 
imaging, restricted range of motion of the instruments, and poor 
ergonomic positioning of the surgeon. Moreover, indications to 
treat advanced gastric cancers by MIS still remain to be defined.3,6,7
The robotic surgery system was introduced as a solution to 
minimize the shortcomings of laparoscopy. This emerging method 
provides undoubted technical advantages over conventional lapa-
roscopy,8 but its role for gastric cancer is still unclear.9-14 Since 
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robotic gastrectomy (RG) has been reported,8,15 the application of 
this new approach is increasing in experienced centers. Yet, to date 
only a limited number of studies have focused on this new method. 
Thus, we have performed a meta-analysis of studies that have 
compared RG with open gastrectomy (OG) and with LG for gastric 
cancer. In the era of rapid penetration of robotic technology, we 
specifically aimed to systematically and objectively assess the value 
of RG for the treatment of gastric cancer.
Materials and Methods
1. Search strategy
Publications were identified by searching the major medical 
databases, such as PubMed, EMBASE, and the Cochrane Library 
for all articles published until July 19, 2012. We adopted the MeSH 
form strategy for PubMed and the Cochrane Library as follows: 
(stomach cancer or gastric cancer or stomach neoplasm or gastric 
neoplasm or stomach carcinoma or gastric carcinoma or stomach 
tumor or gastric tumor or stomach tumour or gastric tumour or 
stomach neoplasms or gastric neoplasms) and (robot or robotic or 
robotics). We used the Emtree form strategy for EMBASE as re-
ported: (‘stomach cancer’ or ‘gastric cancer’ or ‘stomach neoplasm’ 
or ‘gastric neoplasm’ or ‘stomach carcinoma’ or ‘gastric carcinoma’ 
or ‘stomach tumor’ or ‘gastric tumor’ or ‘stomach tumour’ or ‘gastric 
tumour’) and (robot or robotic or robotics).
2. Inclusion and exclusion criteria with quality of 
literature 
Inclusion criteria were: (1) observational studies that compared 
RG versus OG or LG or both with lymph node dissection for 
the treatment of gastric cancer; (2) patients with primary gastric 
adenocarcinoma; and (3) data which included most of the follow-
ing: operation time, blood loss, number of harvested lymph nodes, 
hospital stay, and morbidity. Exclusion criteria were: (1) gastroin-
testinal stromal tumors or benign gastric diseases; and (2) duplicate 
publication or the publication that did not provide sufficient data for 
the analyses.
Two of the authors (M.A., Y.Y.C.) evaluated the eligibility of all 
studies independently collected from the databases based on the 
selection criteria. The risk of bias in each study was assessed ac-
cording to the Newcastle-Ottawa Scale for observational studies.16
3. Data extraction
Two researchers (M.A., Y.Y.C) extracted data from each study 
using a structured sheet and entered the data into a database. An-
other author (J.K.) reviewed this process. The following factors 
were examined: author, year of publication, source journal, sample 
size, characteristics of the patients, research design, operative time, 
blood loss, number of harvested lymph nodes, morbidity, and 
length of hospital stay.
Fig. 1. Flow diagram for identification of selected articles. Seven cohort studies were finally included in the meta-analysis. RG = robotic gastrec-
tomy; OG = open gastrectomy; LG = laparoscopic gastrectomy.
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4. Statistical analysis
We conducted a meta-analysis with the software Review Man-
ager (RevMan) ver. 5.1 by the Cochrane Collaboration (Nordic 
Cochrane Center, Copenhagen, Denmark). We calculated the effect 
sizes by odds ratio (OR) for dichotomous variables and weighted 
mean differences (WMD) for continuous outcome measures with 
95% confidence intervals (CIs). The Higgins I2 and chi-square tests 
were used to evaluate the heterogeneity of the results across studies. 
We considered a P-value of chi-square less than 0.10 with an I2-
value of greater than 50% as indicative of substantial heterogeneity. 
The inverse variance method with fixed-effects model was applied 
if no heterogeneity was considered, whereas the random effects 
model was used in opposite cases. The correction of the zero cell 
counts was automatically performed by the RevMan program with 
Table 1. Selected studies
Author Country and year Surgery Number of patient Resection extent of surgery (TG/SG)
LN dissection
(D1+α or β/D2)
Depth of 
invasion
Kim et al.17 South Korea, 2010 RG 16 0/16 2/14 <T2N1MO
LG 11 0/11 3/8
OG 12 0/12 0/12
Pugliese et al.18 Italy, 2010 RG 18 0/18 0/18 EGC+AGC
LG 52 0/52 0/52
Yoon et al.19 South Korea, 2012 RG 36 36/0 NA <T2N1MO
LG 65 65/0 NA
Woo et al.20 South Korea, 2011 RG 236 62/172 13/105 <T2N1MO
LG 591 108/481 312/279
Eom et al.21 South Korea, 2012 RG 30 0/30 10/20 EGC
LG 62 0/62 28/34
Caruso et al.22 Italy, 2011 RG 29 12/17 0/29 EGC+AGC
OG 120 37/83 0/120
Huang et al.23 Taiwan, 2012 RG 39 7/32 5/34 <T2N1MO
LG 64 7/57 52/12
OG 586 179/407 70/516
TG = total gastrectomy; SG = subtotal gastrectomy; LN = lymph node; RG = robotic gastrectomy; LG = laparoscopic gastrectomy; OG = open 
gastrectomy; NA = not available; EGC = early gastric cancer; AGC = advanced gastric cancer.
Table 2. The assessment of the risk of bias in each study using the Newcastle-Ottawa scale 
Type of study Study
Selection (0~4) Comparability (0~2) Outcome (0~3)
Total
REC SNEC AE DO SC AF AO FU AFU
Cohort studies Kim et al.17 * * * * * * 6
Pugliese et al.18 * * * * * * * 7
Yoon et al.19 * * * * * * * 7
Woo et al.20 * * * * * * 6
Eom et al.21 * * * * * * 6
Caruso et al.22 * * * * * * 6
Huang et al.23 * * * * * 5
REC = representativeness of the exposed cohort; SNEC = selection of the non-exposed cohort; AE = ascertainment of exposure; DO = 
demonstration that outcome of interest was not present at start of study; SC = study controls for age, sex, marital status; AF = study controls for 
any additional factors; AO = assessment of outcome; FU = follow-up long enough for outcomes to occur; AFU = adequacy of follow-up of cohorts. 
*Asterisk means that the study is satisfied the item, and no asterisk means the opposite situation.
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exclusion of the outcome from the meta-analysis if there was no 
event in both arms in one study. We obtained the standard devia-
tion from the article by contacting the authors by e-mail if it was 
not reported or by extracting the estimated standard deviation from 
the P-value 「Cochrane Handbook for systematic reviews of in-
terventions version 5.0.2」 if it was not directly available from the 
authors. The symmetry of Begg’s funnel plot was used to evaluate 
the presence of publication bias in the studies. 
Results
From a total of 190 articles seven17-23 were selected according to 
our inclusion and exclusion criteria (Fig. 1). All are non-random-
ized, non-blinded, retrospective cohort studies. The characteristics 
of the seven selected articles are shown in Table 1.
Next to the intraoperative outcomes, this analysis was directed 
at the short-term results of RG because long-term outcomes were 
not sufficiently addressed by the included studies. A total of 1,967 
patients affected by gastric cancer were analyzed, including 404 
who underwent RG, 718 who underwent OG, and 845 who under-
went LG. The risk of bias of included studies is shown in Table 2, 
whereby two received seven stars, one received five stars, and the 
remaining received six stars. The mean number of stars for the risk 
of bias was 6.1. Each meta-analysis was performed twice; with 
Fig. 2. Forest plots of studies comparing robotic gastrectomy (RG) vs. open gastrectomy (OG) for gastric cancer. (A) Operative time. (B) Blood loss. 
(C) Number of harvested lymph-nodes. (D) Overall complication rate. (E) Hospital stay. SD = standard deviation; CI = confidence interval; df = 
degree of freedom.
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Fig. 2. Continued.
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all available studies and those including only complete data which 
was analyzed excluding the study showing results with high risk of 
bias.23 The forest plots of each outcome, subdivided in two different 
groups, are shown in Fig. 2 and 3. 
1. Comparing RG with OG
We found that three out of seven selected articles compared RG 
to OG (Table 1). The operative time, amount of blood loss, number 
of lymph nodes retrieved, overall complications, and hospital stay 
Fig. 3. Forest plots of studies comparing robotic gastrectomy (RG) vs. laparoscopic gastrectomy (LG) for gastric cancer. (A) Operative time. (B) 
Blood loss. (C) Number of harvested lymph nodes. (D) Overall complication rate. (E) Hospital stay. SD = standard deviation; CI = confidence in-
terval; df = degree of freedom.
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were analyzed. Detailed information about these outcomes was 
available in all three selected studies.  
The operative time in the robotic group was significantly longer 
than in the open group (WMD: 95.83, 95% CI: 54.48 to 137.18, 
P＜0.00001) in a random effect model (P=0.002, I2: 84%). After 
exclusion of insufficient data the operative time was still signifi-
Fig. 3. Continued.
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cantly longer in the robotic group (WMD: 100.91, 95% CI: 37.72 
to 164.11, P=0.002) in a random effect model (P=0.0008, I2: 91%). 
The blood loss was less in RG than OG, but without statistical 
significance (WMD: -225.58, 95% CI: -478.88 to 27.72, P=0.08) 
in a random effect model (P＜0.0001, I2: 98%). By considering 
only complete data, the analysis revealed the same results (WMD: 
-114.88, 95% CI: -251.90 to 22.13, P=0.10) in a random effect 
model (P=0.002, I2: 90%). The number of lymph nodes retrieved 
was higher in the open group compared with the robotic group, 
though without a statistically significant difference (WMD: -2.68, 
95% CI: -5.74 to 0.38, P=0.09) in a fixed effect model (P=0.88, I2: 
0%). The same non-significant outcomes in favor of OG (WMD: 
-3.28, 95% CI: -7.48 to 0.91, P=0.13) were noted when including 
only complete data in a fixed effect model (P=0.75, I2: 0%). The 
overall complication rate between the two comparative surgical ap-
proaches did not show any significant difference (OR: 0.93, 95% 
CI: 0.51 to 1.68, P=0.81) in a fixed effect model (P=0.44, I2: 0%). 
Additionally, when considering only valid data, the robotic and 
open groups did not differ significantly in regards to morbidity (OR: 
0.84, 95% CI: 0.38 to 1.86, P=0.66) in a fixed effect model (P=0.22, 
I2: 33%). However, the hospital length of stay for the robotic group 
was significantly shorter than for the open group (WMD: -2.92, 
95% CI: -4.94 to -0.89, P=0.005) in a random effect model (P=0.04, 
I2: 69%). Analysis of data extracted only from the articles includ-
ing complete data 17,22 also revealed an outcome with a significant 
difference in favor of the robotic group (WMD: -2.54, 95% CI: 
-4.67 to -0.41, P=0.02) in a random effect model (P=0.03, I2: 78%). 
Fig. 4 shows the symmetry of the funnel plots in each outcome. 
Estimation of publication bias by funnel plot was difficult as there 
were only three publications which compared RG to OG. However, 
publication bias was suspected among the overall complications. 
2. Comparing RG to LG
We found that six out of the seven selected articles compared 
RG to LG (Table 1). The operative time, amount of blood loss, 
number of lymph nodes retrieved, overall complications, and hos-
pital length of stay were examined. All six articles reported their 
respective data regarding these particular parameters; however, 
one report19 compared the amount of blood loss by the change in 
the hemoglobin level, and this parameter was excluded from this 
specific analysis. We found that the operative time for RG was 
significantly longer than for LG (WMD: 63.70, 95% CI: 44.22 to 
83.17, P＜0.00001) in a random effect model (P=0.002, I2: 74%). 
The results were the same when considering only complete articles, 
with similar statistical significance (WMD: 65.82, 95% CI: 43.27 to 
88.37, P＜0.00001) in a random effect model (P=0.0007, I2: 79%). 
The amount of blood loss was also significantly less for RG than 
for LG (WMD: -35.53, 95% CI: -66.98 to -4.09, P=0.03) in a 
Fig. 3. Continued.
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random effect model (P=0.003, I2: 75%). By including only valid 
data, analysis of the pooled data revealed that the estimated blood 
loss was not significantly less for RG than for LG (WMD: -27.82, 
95% CI: -63.60 to 7.95, P=0.13) in a random effect model (P=0.002, 
I2: 79%). Likewise, our analysis of the number of lymph nodes re-
trieved demonstrated no significant difference between RG and LG 
(WMD: 0.50, 95% CI: -3.30 to 4.30, P=0.80) in a random effect 
model (P=0.0001, I2: 80%). Analysis of this variable by considering 
only valid articles also revealed that there was no significant dif-
ference in the number of lymph nodes retrieved (WMD: 0.54, 95% 
CI: -4.51 to 3.42, P=0.79) in a random effect model (P=0.0006, I2: 
80%). The overall complication rate of each surgical approach was 
Fig. 4. Begg’s funnel plots for identifying publication bias for five perioperative outcomes regarding robotic vs. open and laparoscopic gastrectomy. 
(A) Operative time. (B) Blood loss. (C) Number of harvested lymph nodes. (D) Overall complication rate. (E) Hospital stay. RG = robotic gastrec-
tomy; OG = open gastrectomy; LG = laparoscopic gastrectomy; SE = standard error; MD = mean difference; OR = odds ratio.
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not different between the groups (OR: 0.87, 95% CI: 0.59 to 1.27, 
P=0.46) in a fixed effect model (P=0.69, I2: 0%). Inclusion of only 
the articles that matched our quality assessment did not change the 
final results, as even in this analysis there was no significant dif-
ference in the overall complication rate (OR: 0.85, 95% CI: 0.57 to 
1.28, P=0.44) in a fixed effect model (P=0.56, I2: 0%). Likewise, the 
duration of hospital stay was not significantly different between the 
RG and LG groups (WMD: -0.60, 95% CI: -1.66 to 0.45, P=0.26) 
in a random effect model (P＜0.00001, I2: 87%). Similar results 
were observed when considering properly sufficient data (WMD: 
-0.43, 95% CI: -1.46 to 0.61, P=0.42) in a random effect model 
(P＜0.00001, I2: 89%). Fig. 4 shows the symmetry of the funnel 
plot for each outcome. Asymmetry was suspected for the amount 
of blood loss, the overall complications, and the hospital length of 
stay.
Discussion
The aim of this meta-analysis was to compare RG to OG and 
LG by means of a thorough evaluation of the available data. Most 
studies demonstrated similar advantages to RG, including a reduced 
intraoperative blood loss and shorter hospital stay compared with 
OG and less intraoperative blood loss compared with LG. These 
results suggest that robotic surgery can be especially useful for 
selected patients affected by gastric cancer with severe anemia, as 
some authors have already published.20 This is important as trans-
fusion-related problems and risk of gastric cancer recurrence could 
be reduced.24-26
Lymph node dissection is a fundamental part of a radical gas-
trectomy. In this meta-analysis the overall number of lymph nodes 
retrieved was high, which is explained by many studies with D2 
lymphadenectomies.27 Evaluation of the pooled data revealed that 
the number of lymph nodes dissected with RG was less than with 
OG but greater than with LG, though these differences were not 
significant. A possible explanation for the high number of lymph 
nodes retrieved with OG might be that comparative groups of 
two22,23 of the three pooled studies were heavily unbalanced by 
centers highly skilled with OG. Moreover, most patients enrolled 
Fig. 4. Continued.
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in these two open groups were affected by advanced gastric cancer. 
Therefore, since a more extended lymphadenectomy is recom-
mended for advanced stages,28,29 one might expect the number of 
lymph nodes retrieved to be higher than in early stages, which are 
more common in the robotic group. Nonetheless, even in compari-
son with the open approach, RG guarantees the removal of at least 
15 lymph nodes which still allows for proper staging and prog-
nostication. This is important because it favors greater rates of sur-
vival.30,31 All told, these results demonstrate that RG can be safely 
performed with adequate oncological principles compared to either 
OG or LG. RG could also be used for D2 lymphadenectomies, 
although it was not possible to analyze whether D2 lymphadenec-
tomies were validated by any approach. 
These positive results derive from some technical and evidence-
based aspects to robotic surgery, such as superior 3-dimensional 
visualization, more degree of freedom of the wristed-tip instru-
ment, and tremor-filtered control of the four robotic arms.8,13 
These emerging tools may improve a surgeon’s dexterity when fine 
manipulation of tissues in a close, fixed operating field is required, 
or when hand-sewn sutures and knot-tying are a necessity. The 
robotic technique provides an easier lymph node dissection, a re-
duced inflammatory response, less manipulation of the tissues, and 
a quicker bowel recovery which are reflected by a reduced intraop-
erative blood loss, a shorter hospital stay, and an easier lymphad-
enectomy compared with other approaches.17 
Some limitations were present in our meta-analysis. The quality 
assessment of all seven selected articles is shown in Table 2. One 
work had a score of ＜6 points,23 whereas the remaining studies 
all had a valuation of ≥6 points.17-22 Our purpose was to obtain a 
good quality meta-analysis, but the pooled studies were limited in 
number. Thus, we decided to compare all selected variables both 
considering all seven reports as well as excluding only the work that 
did not match our quality assessment.23 This decision was aimed 
at reducing potential bias and to assess for any differences in the 
results between the two specific groups. According to this strategy, 
the only difference considering the complete data was regarding the 
estimated blood loss, which was less in RG vs. LG, though without 
statistical significance (Fig. 3B).
Another limitation is that significant heterogeneity was rec-
ognized in some characteristics of the selected articles. Most of 
the pooled studies included patients who underwent both subtotal 
gastrectomy and total gastrectomy without distinction. Further-
more, surgeons performed both robotic gastrectomies and robotic-
assisted gastrectomies. The stage of gastric cancer was also not the 
same for all of the enrolled patients. For instance, inclusion of pa-
tients was specifically limited to early gastric cancer in one study,21 
three reports considered patients with both early and advanced 
gastric cancer,18,22,23 and three articles17,19,20 included patients with 
a preoperative clinical stage Ia or Ib disease. With the exception 
of one report,19 the intended extent of lymph node dissection was, 
however, defined for the RG, LG, and OG groups in all studies 
(namely D1+β or D2) (Table 1). Finally, the majority of the stud-
ies were from Asian populations and accounted for 1,748 of the 
patients,17,19-21,23 whereas the remaining two reports were European, 
consisting of 219 patients.18,22 This is relevant as gastric cancer is less 
common in Western countries where it is diagnosed at later stages 
since screening in Europe is not routine.32 Additionally, Asian sur-
geons have been the first to embrace the new robotic system, and 
to date they continue to perform many robotic gastrectomies in 
experienced centers. Therefore, it is difficult to generalize the find-
ings of this meta-analysis to worldwide populations of patients with 
gastric cancer.
To date, only one Chinese meta-analysis comparing RG vs. LG 
has been published.33 The authors selected three studies from an 
initial collection of 52 articles up to December 2011 according to 
specific criteria. This resulted in a comparison of 268 patients un-
dergoing RG vs. 650 undergoing LG. This Chinese meta-analysis 
did have some limitations which are acknowledged by the authors, 
including a limited number of published studies, small sample size, 
and short duration of follow-up. Indeed, each of these weaknesses 
is also present in our work, though ours differs in some aspects. 
First, the aim of our meta-analysis was to compare RG with both 
OG and LG, for this aspect it can be considered the first one. 
Second, we collected all 190 articles present in the literature up to 
July 2012 using an accurate research strategy. We contacted each 
author if some data of interest were lacking, whereas if data were 
unavailable, we noted this as incomplete in the database. Finally, 
we decided to perform a strategic double comparison in order to 
minimize possible bias since we realized that not all of the seven 
selected articles had enough quality level data and since the number 
of patients overall was relatively small. 
Nevertheless, our meta-analysis still has some important short-
comings. The pooled studies are all retrospective and obviously 
limited. The number of patients entered is relatively small and 
sometimes comparative groups are unbalanced, which may gloss 
over true differences among some variables. Moreover, some char-
acteristics are not mentioned in all of the pooled studies, such as 
type of surgical reconstruction, stage of the tumor, short and long-
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term outcomes, and follow-up period. For instance, in two of the 
articles,22,23 the groups do not have the same period of recruitment. 
Additionally, in another of the two studies, the patients were drawn 
from the same database;19,21 although, in one report, only patients 
who underwent subtotal gastrectomy were enrolled, while in the 
other report, only those who had received a total gastrectomy were 
considered. A final important deficiency in our work is the com-
plete lack of information regarding costs, which could represent a 
real and incontrovertible problem. So far, only one article is present 
in the literature 21 that has reported some information regard-
ing this aspect. Even if in the near future some other authors do 
focus on this topic it will remain very difficult to evaluate the cost 
of the robotic approach and compare it to that of more traditional 
methods. This is relevant as more than one insurance system is 
often present in each country and because insurance systems dif-
fer between countries. Furthermore, the price of the instruments 
and the devices is also not equivalent worldwide. Since each type of 
uniformity cannot be guaranteed, it is likely that the tools generally 
recognized for the assessment of costs will not be provided.
Many high quality prospective studies must be performed in 
order to assess the safety and efficacy of RG for the treatment 
of gastric cancer in the near future. In addition to the outcomes 
reported in this article, future studies should be directed at more 
detailed oncologic findings, survival, and costs. Currently, a multi-
center prospective analysis regarding the advantage of RG vs. LG 
(NCT01309256) is in process in Korea, representing a good effort 
to assess the validity of RG. 
In conclusion, our meta-analysis is the most accurate and up-
dated work present in the literature and it can be considered as the 
starting point for subsequent investigations. Our study demonstrates 
that RG for gastric cancer is a promising new surgical technique 
that reduces blood loss and postoperative hospital stays compared 
with LG and OG, though at the price of longer operating times. 
RG also allows for an oncologically correct lymphadenectomy for 
gastric cancer treatment.
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